Akari Therapeutics Plc（AKTX）美股招股说明书 S-1（2026-06-26修订版）（英文版）（45页）.pdf

1、S-1/A 1 forms-1a.htm S-1/A As filed with the Securities and Exchange Commission on June 26,2026 Registration No.333-289962 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549 Amendment No.1 to FORM S-1 REGISTRATION STATEMENTUNDERTHE SECURITIES ACT OF 1933 AKARI THERAPEUTICS,PLC(Exact

2、 name of registrant as specified in its charter)England and Wales 2834 98-1034922(State or other jurisdictionof incorporation or organization)(Primary Standard IndustrialClassification Code)(I.R.S.EmployerIdentification No.)401 East Jackson Street,Suite 3300Tampa,FL 33602(929)274-7510(Address,includ

3、ing zip code,and telephone number,including area code,of registrants principal executive offices)Abizer GaslightwalaPresident and Chief Executive Officer401 East Jackson Street,Suite 3300Tampa,FL 33602(929)274-7510(Name,address,including zip code,and telephone number,including area code,of agent for

4、 service)Copies to:Dov T.Schwell,Esq.Schwell Wimpfheimer&Associates LLP37 West 39th Street,Suite 505New York,New York 10018Tel:(646)328-0850Fax:(646)360-5000 Approximate date of commencement of proposed sale to the public:From time to time after this RegistrationStatement becomes effective.If any of

5、 the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415under the Securities Act of 1933,check the following box.If this Form is filed to register additional securities for an offering pursuant to Rule 462(b)under the Securities Act,please

6、check the following box and list the Securities Act registration statement number of the earlier effective registration statement forthe same offering.If this Form is a post-effective amendment filed pursuant to Rule 462(c)under the Securities Act,check the following box andlist the Securities Act r